Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of mRNA-1273.214 SARS-CoV-2 vaccine in infants aged 12 weeks to under 6 months
2023-000482-14Phase 2
- Sponsor
- Moderna Inc
- Start
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elasomeran + imelasomeran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Moderna Inc. Primary endpoint: Number of participants with solicited local and systemic adverse reactions.
02
Drugs
elasomeran + imelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2023-000482-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000482-14.